Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00391846 |
The purpose is to study if HF treatment guided by NTproBNP in addition to clinical symptoms and signs is more effective than treatment guided by clinical symptoms and signs alone in patients with HF and left ventricular systolic dysfunction
Condition | Intervention | Phase |
---|---|---|
Heart Failure Ventricular Dysfunction, Left |
Drug: Captopril Drug: Enalapril Drug: Lisinopril Drug: Ramipril Drug: Trandolapril Drug: Bisoprolol Drug: Carvedilol Drug: Metoprolol succinate Drug: Candesartan Drug: Valsartan Drug: Eplerenone Drug: Spironolactone Drug: Diuretics Drug: HF treatment according to Swedish guidelines Procedure: Blood samples Procedure: KCCQ Questionnaire |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind (Subject), Active Control, Parallel Assignment, Efficacy Study |
Official Title: | A Randomised, Single Blind, Multicentre, 9-Month, Phase IV Study, Comparing Treatment Guided by Clinical Symptoms and Signs and NT-proBNP vs Treatment Guided by Clinical Symptoms and Signs Alone, in Patients With HF and Left Ventricular Systolic Dysfunction |
Estimated Enrollment: | 250 |
Study Start Date: | October 2006 |
Estimated Study Completion Date: | February 2009 |
Estimated Primary Completion Date: | January 2009 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Sweden | |
Research Site | |
UMEA, Sweden | |
Research Site | |
UPPSALA, Sweden | |
Research Site | |
VASTERAS, Sweden | |
Research Site | |
ALVESTA, Sweden | |
Research Site | |
ARVIKA, Sweden | |
Research Site | |
BJUV, Sweden | |
Research Site | |
BORENSBERG, Sweden | |
Research Site | |
BROMMA, Sweden | |
Research Site | |
DALBY, Sweden | |
Research Site | |
ESKILSTUNA, Sweden | |
Research Site | |
GAGNEF, Sweden | |
Research Site | |
G�TEBORG, Sweden | |
Research Site | |
HISINGS K�RRA, Sweden | |
Research Site | |
HUDDINGE, Sweden | |
Research Site | |
HUSKVARNA, Sweden | |
Research Site | |
J�NK�PING, Sweden | |
Research Site | |
KALMAR, Sweden | |
Research Site | |
KUNG�LV, Sweden | |
Research Site | |
LERUM, Sweden | |
Research Site | |
LESSEBO, Sweden | |
Research Site | |
V�XJ�, Sweden | |
Research Site | |
LILLA EDET, Sweden | |
Research Site | |
LINK�PING, Sweden | |
Research Site | |
LUDVIKA, Sweden | |
Research Site | |
LYCKEBY, Sweden | |
Research Site | |
MALM�, Sweden | |
Research Site | |
MOHEDA, Sweden | |
Research Site | |
MOTALA, Sweden | |
Research Site | |
�REBRO, Sweden | |
Research Site | |
�STERSUND, Sweden | |
Research Site | |
SKAN�R, Sweden | |
Research Site | |
S�DER�KRA, Sweden | |
Research Site | |
STENUNGSUND, Sweden | |
Research Site | |
STOCKSUND, Sweden | |
Research Site | |
TIMR�, Sweden | |
Research Site | |
UDDEVALLA, Sweden | |
Research Site | |
ULRICEHAMN, Sweden | |
Research Site | |
V�STER�S, Sweden | |
Research Site | |
V�STERVIK, Sweden | |
Research Site | |
LIDK�PING, Sweden |
Study Director: | AstraZeneca Sweden Medical Director, MD | AstraZeneca |
Principal Investigator: | Hans Persson, MD, PhD | Danderyd Hospital, Sweden |
Study Director: | Bjorn Eriksson, MD | AstraZeneca |
Responsible Party: | Medical Department, AstraZeneca ( Björn Ericsson, MD, Director Medical Affairs, AZ Sweden ) |
Study ID Numbers: | D2452L00010, EUDRACT No. 2006-001259-36, SIGNAL HF |
Study First Received: | October 19, 2006 |
Last Updated: | November 10, 2008 |
ClinicalTrials.gov Identifier: | NCT00391846 |
Health Authority: | Sweden: Medical Products Agency |
Heart Failure Ventricular Dysfunction NTproBNP |
Captopril Ventricular Dysfunction Heart Failure Heart Diseases Lisinopril Angiotensin II Metoprolol Ramipril Spironolactone Candesartan cilexetil Signs and Symptoms |
Bisoprolol Eplerenone Enalapril Trandolapril Enalaprilat Metoprolol succinate Candesartan Ventricular Dysfunction, Left Valsartan Carvedilol |
Neurotransmitter Agents Vasodilator Agents Molecular Mechanisms of Pharmacological Action Adrenergic Agents Cardiotonic Agents Hormone Antagonists Physiological Effects of Drugs Diuretics Hormones, Hormone Substitutes, and Hormone Antagonists Therapeutic Uses Adrenergic beta-Antagonists Angiotensin-Converting Enzyme Inhibitors Cardiovascular Diseases Anti-Arrhythmia Agents |
Sympatholytics Enzyme Inhibitors Cardiovascular Agents Adrenergic alpha-Antagonists Antihypertensive Agents Protective Agents Pharmacologic Actions Protease Inhibitors Angiotensin II Type 1 Receptor Blockers Aldosterone Antagonists Autonomic Agents Natriuretic Agents Adrenergic Antagonists Peripheral Nervous System Agents |